📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
News
Sygnature Discovery boosts North American growth with new General Manager
World-leading contract research organization Sygnature Discovery has announced a major new addition to its leadership…
Journal Papers
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, Philip MacFaul, Andrew Novak, Guillaume Revol, Etienne Rochette, Allan Jordan Abstract The field of induced proximity…
News
Sygnature Discovery Unlocks Life-Changing Treatment Options with New Human Disease Modeling Platform
Sygnature Discovery has unveiled its humanized neuroinflammation in vitro platform, SCANME (SCreening for…
Blog
A Comparison of the Structural Techniques used at Sygnature Discovery: X-ray Crystallography, NMR and Cryo-EM
In this article we discuss the three techniques used for determining protein and nucleic acid…
Webinars & Podcasts
iPSCs in Neuroscience Drug Discovery
Could iPSCs be the breakthrough we need in neuroscience drug discovery?
News
Sygnature Discovery has Chosen Elsevier as New Preferred Partner to Empower its Global Team of Chemists
Sygnature Discovery is pleased to announce its new partner Elsevier, a global information and analytics…
Journal Papers
Novel Macrocyclic NLRP3 Inhibitors
Stefanie Mesch, Jonathan Shannon, David Miller, Angus MacLeod, Léa Bouché, Heather J. Johnston, Kim Matthews,…
Case Studies
How do you find novel molecular glues? A biophysical approach to molecular glue hit ID
Well-characterized hits provide a strong foundation for experienced drug discovery teams to rapidly advance a…
Journal Papers
5-HT1B receptor activation produces rapid antidepressant-like effects in rodents
Ketamine is noted for its rapid onset antidepressant response and effectiveness in patients with treatment resistant depression. While most research has focused on glutamatergic mechanisms, recent studies show that antidepressant-like effects in rodents are dependent upon the serotonergic (5-HT) system and suggest a potential contribution of the 5-HT1B receptor.
Case Studies
Executing hit-finding against a novel nucleic acid binding complex – a structurally enabled approach identifying hits against different complex states
Well-characterized hits provide a strong foundation for experienced drug discovery teams to rapidly advance a…
News
Sygnature Discovery appoints Rick Davies to spearhead growth as Director of its UK Protein Sciences and Structural Biology business (formerly, Peak Proteins)
Sygnature Discovery is delighted to announce the appointment of Rick Davies as Director…
Case Studies
Early Validation of HTS hits using X-ray Crystallography
Well-characterized hits provide a strong foundation for experienced drug discovery teams to rapidly advance a…
News
Sygnature Discovery Appoints New Chief Commercial Officer to Drive Next Phase of Business Growth
Sygnature Discovery has announced the appointment of Kieron Hall as its new Chief…
Blog
Unlocking the Power of Phenotypic Screening in Drug Discovery
In the vast landscape of drug discovery, where the journey from concept to…
News
Sygnature Discovery boosts growth of its in vivo Pharmacology business with appointment of new Vice President
Sygnature Discovery is thrilled to announce the appointment of Fraser McIntosh as Vice…
Blog
Phenotypic screening for inflammasome modulators: A powerful example of a high content phenotypic screening approach where there are complex biological systems.
Using a phenotypic approach for HTS HTS is a ubiquitous and…
Journal Papers
Digitalizing the Design-Make-Test-Analyze Workflow in Drug Discovery with an Electronic Inventory Platform
Ting Qin, Aparna Chandrasekaran, Jason Shiers, Matthew Crittall, Ciaran O’Reilly, Colin Sambrook Smith Abstract Drug…
Journal Papers
Lysosomal Ion Channels and Transporters: Recent Findings, Therapeutic Potential, and Technical Approaches
Artem Kondratskyi , Andre Bazzone, Markus Rapedius, Rocco Zerlotti, Bastien Masson, Nidish Ponath Sadanandan, Joanne L Parker, Alexandre Santinho, Marine Moutia, Abdou Rachid Thiam, Arlene Kemp, Fitzwilliam…
Webinars & Podcasts
Next Gen ADCs – What’s Changing & Why Should Companies Care?
While others focus on a conventional and well trodden ADC development pathway, Allan Jordan (VP, Oncology Drug Discovery) and Josh Greally (ADC Lead) discuss new approaches. This includes a focus on payload optimisation to enhance a drug’s efficacy and selectivity, thereby maximizing its therapeutic benefit. Better performing end products lead to better patient outcomes.
Webinars & Podcasts
Choosing the Right Payload: What Makes a Small Molecule Suitable for an ADC
While others focus on a conventional and well trodden ADC development pathway, Allan Jordan (VP, Oncology Drug Discovery) and Josh Greally (ADC Lead) discuss new approaches. This includes a focus on payload optimisation to enhance a drug’s efficacy and selectivity, thereby maximizing its therapeutic benefit. Better performing end products lead to better patient outcomes.
Webinars & Podcasts
Linker Technologies in ADCs: How They Impact Efficacy and Stability
While others focus on a conventional and well trodden ADC development pathway, Allan Jordan (VP, Oncology Drug Discovery) and Josh Greally (ADC Lead) discuss new approaches. This includes a focus on payload optimisation to enhance a drug’s efficacy and selectivity, thereby maximizing its therapeutic benefit. Better performing end products lead to better patient outcomes.
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch